Latest MS research news

Latest MS research news | 11 December 2013

Long-term effects of dalfampridine in patients with multiple sclerosis

This study looked at the short and long term effects of treatment with dalfampridine on motor and cognitive measures in MS patients over a nine to 12 month period.

From MSIF

Latest MS research news | 11 December 2013

Smokers run increased risk of developing anti-natalizumab antibodies

This study showed that smoking during or close to the time of treatment with natalizumab (Tysabri) was associated with an increased risk of developing antibodies against natalizumab.

From MSIF

Latest MS research news | 11 December 2013

Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS

This study showed that the BCG vaccine, when compared to placebo, was associated with a definite reduction in the development of gadolinium-enhancing lesions on MRI in subjects with a clinically isolated syndrome.

From MSIF

Latest MS research news | 03 December 2013

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

This study provides further evidence that sodium blockers have the potential to limit nerve loss in the progressive phase of MS in the animal model. By targeting this class of agent, this may slow neurodegeneration in MS.

From MSIF

Latest MS research news | 03 December 2013

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis

This study looked at specific types of RNA (called micro RNAs), which are involved in the regulation of gene expression. The researchers found that levels of these in the blood were decreased in MS patients compared to controls.

From MSIF

Latest MS research news | 03 December 2013

Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis

This study compared demographic and clinical characteristics of patients with RRMS who did or did not switch disease modifying therapy after experiencing an MS-related clinical event.

From MSIF

Latest MS research news | 26 November 2013

Cortical plasticity predicts recovery from relapse in multiple sclerosis

This study showed that increased long term potentiation measured at the time of relapse was associated with an improved clinical recovery after a relapse, which may represent an important player for recovery.

From MSIF

Latest MS research news | 26 November 2013

Disclosure of diagnosis of multiple sclerosis in the workplace positively affects employment status and job tenure

This interesting study looked at the importance of disclosure of diagnosis of MS in the workplace and showed that disclosure to an employer increases job retention.

From MSIF

Latest MS research news | 26 November 2013

Using magnetic resonance imaging in animal models to guide drug development in multiple sclerosis

This review article looks at the importance of incorporating MRI into animal studies testing new potential treatments in MS.

From MSIF

Latest MS research news | 19 November 2013

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population

The effects of starting fingolimod on the heart remain consistent with results from previous studies, even when patients with pre-existing cardiac conditions are included.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial